VTGN - VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02 revenue of $0.18M misses by $0.13M
- VistaGen Therapeutics press release ( NASDAQ: VTGN ): Q3 GAAP EPS of -$0.05 beats by $0.02 .
- Revenue of $0.18M (-50.0% Y/Y) misses by $0.13M .
- At December 31, 2022, the Company had cash and cash equivalents of approximately $25.0 million.
For further details see:
VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.18M misses by $0.13M